Back to School: How biopharma can reboot drug development. Access exclusive analysis here

CMS giveth, taketh away

CMS giveth, taketh away

Drug Company Indication 2002 Rate (B) 2004 Proposed Rate (B) $ chg % chg
Prolastin alpha-1 proteinase inhibitor Bayer Replacement

Read the full 260 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE